Skip to main
STE
STE logo

STERIS (STE) Stock Forecast & Price Target

STERIS (STE) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 0%
Buy 83%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Steris reported total revenue of $1,480.5 million for F4Q25, reflecting a 5.0% year-over-year increase on an organic basis, with a stronger performance of 5.9% when adjusted for constant currency. The company's EBIT margin also demonstrated positive momentum, rising by 110 basis points year-over-year, highlighting improved operational efficiency. Furthermore, Steris achieved a quarterly earnings per share (EPS) of $2.74, a 14% increase from the prior year, aided by reduced interest expenses following the strategic divestiture of its dental segment.

Bears say

Steris has reported a notable decline in capital equipment sales, experiencing a decrease of approximately 16% year-over-year, which raises concerns over future revenue generation in a segment that is crucial for overall growth. Additionally, service revenues have fallen by 21% year-over-year, and although consumables showed an 8% increase, the overall revenue mix reflects significant weakness in essential areas of the business. The company's capital equipment backlog has also diminished by $66 million compared to the previous fiscal quarter, indicating potential challenges in sustaining earnings and dividend growth without a recovery in capital equipment demand.

STERIS (STE) has been analyzed by 6 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 83% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of STERIS and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About STERIS (STE) Forecast

Analysts have given STERIS (STE) a Buy based on their latest research and market trends.

According to 6 analysts, STERIS (STE) has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $273.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $273.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

STERIS (STE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.